|Bid||0.1100 x N/A|
|Ask||0.1150 x N/A|
|Day's Range||0.1100 - 0.1150|
|52 Week Range||0.0900 - 0.1800|
|Beta (3Y Monthly)||-1.03|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug. 28, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
MedX Health Corp. (“MedX” or the “Company”) (MDX.V) experienced strong interest for its SIAscopy on DermSecureTM platform from physicians and dermatologists in Brazil during the recent 74th Congress of the Brazilian Society of Dermatology held in Rio de Janeiro in September 2019. “The acceptance of the SIAscopy on DermSecureTM platform at the conference was above our greatest expectations,“ noted Fabio Candello, with the CBD Vida team that will be distributing the product in Brazil. “More than 1,200 Dermatologists and other Specialized Doctors visited our MedX booth to interact with and evaluate this game-changing technology, resulting in more than 200 doctors expressing significant and immediate interest in acquiring MedX’s system.
MedX Health Corp. (“MedX”) (MDX.V) announces that it has signed a non-exclusive, performance-based distribution agreement with Group Vida, to distribute MedX’s DermSecureTM skin cancer assessment technology platform in the USA, Canada and Israel. MedX has previously signed an exclusive distribution agreement for Brazil with CBD Vida LTDA, a Partner of Group Vida. The process for regulatory approval in Brazil is proceeding extremely well according to Peter Abboud, Group Vida’s CEO.
MedX Health Corp. (“MedX”) (MDX.V) announces that it has partnered with SANITAS, a specialist in healthcare and well-being services in Spain, to conduct a skin cancer screening initiative. According to recent studies, Spain, with its warm and sunny climate has experienced a 50% increase in skin cancer rates over the last decade. It is the most common form of cancer in women between the age of 25 and 29, followed by breast cancer, and the most common in men between the age of 30 and 35, ahead of lung and colon cancer.
MedX Health Corp. (“MedX” or the “Company”) (MDX.V) announced its results for the three-months ended March 31, 2019, which are also available on SEDAR (www.sedar.com). The Company reported revenue of $184,801 for the three months ended March 31, 2019, compared with revenue of $226,122 for the three months ended March 31, 2018. Revenues from SIAscopy of $21,563 were lower than the 2018 three-month period, and revenue from the Company's therapeutic laser line of $163,238 were 13% lower than in the prior year.
MedX Health Corp. (“MedX” or the “Company”) (MDX.V) announced its results for the year ended December 31, 2018, which are also available on SEDAR (www.sedar.com). The Company reported revenue of $1,087,426 for the year ended December 31, 2018, compared with revenue of $1,093,239 for the year ended December 31, 2017. Sales from the Company's SIAscopy skin assessment technology increased by 26.5% during 2018, while the sales from the therapeutic laser line were down by 8.7%.
MedX Health Corp. (“MedX” or the “Company”) (MDX.V) is pleased to announce that it has obtained Conditional Approval from the TSX Venture Exchange for a non-brokered Private Placement to accredited investors of up to 15,625,000 units at $0.16 per unit (“Unit”), to raise up to $2,500.000. Each Unit will be comprised of One (1) fully paid common share and One (1) Share Purchase Warrant, exercisable to purchase One (1) further Common Share at the price of $0.25, exercisable for a period of two years from the date of issue. Qualified Agents may receive commissions in respect of subscriptions introduced by them by way of cash equal to 6% of funds so introduced, and issuance of agent’s warrants (“Agent’s Warrant(s)”) equal in number to 6% of the number of units so subscribed for.
MedX Health Corp. (“MedX”) (MDX.V) announced today that it has signed an Exclusive Distribution Agreement with CBD Vida (“Vida”), to launch a comprehensive, ease-of-access skin scanning/assessment program throughout Brazil, using MedX’s DermSecureTM Telemedicine platform. This exclusive distribution agreement is a natural progression of the earlier Memorandum of Understanding with Vida “because their reach in the Brazilian marketplace is robust and extensive,” said Scott Spearn, President & CEO of MedX. There are almost 212 million Brazilian people, where skin cancer is the most common form of cancer,” said Camata Candello, Vida’s CEO.
MedX Health Corp. announces that it has signed an agreement with Richmar, a Compass Health Brands Company, to manufacture and supply selected Private Label Laser and Light products to Richmar for the US rehabilitation market.
MedX Health Corp. (“MedX”) (MDX.V) announces that it has signed a Memorandum of Understanding with CBD Vida LTDA, who plans to launch an ease-of-access skin scanning/assessment program throughout Brazil, using MedX’s DermSecureTM. "There is a significant opportunity for MedX’s skin imaging technology in Brazil, as skin cancer is the most common type of cancer in Brazil,” stated Fabio Camata Candello, CBD Vida LTDA’s CEO. More than one hundred thousand new cases of skin cancer were recorded in Brazil between 2016 and 2017, according to the Brazilian Cancer Institute, and almost 6,000 were classified as melanoma, an aggressive form of the disease that can spread to other parts of the body.
MedX Health Corp. (“MedX” or the “Company”) (MDX.V) announces that, pursuant to a non-brokered Private Placement Offering (the “Placement Offering”), it has completed an initial Closing of 2,962,500 Units on January 28, 2019, to raise $474,000 from accredited investors pursuant to a Private Placement Offering originally announced on November 23, 2018. This Closing, and any further Closing of the Placement Offering, is subject to all relevant regulatory and other consents and approvals, including acceptance by the TSX Venture Exchange. MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology.